Tech Company M&A Transactions
Tensha Therapeutics Acquisition
Tensha Therapeutics was acquired by Roche. The transaction was announced on 1/11/2016. The acquisition price was $535 million.
Transaction Overview
Company Name
Acquired By
Announced On
1/11/2016
Transaction Type
M&A
Amount
$535,000,000
M&A Terms
Under the terms of the agreement, Tensha's shareholders will receive an upfront cash payment of $115 million, plus additional contingent payments of up to $420 million based on the achievement of certain predetermined clinical and regulatory milestones.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
55 Cambridge Parkway 102
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Not Recorded
Overview
Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Founder
James Bradner
Browse more venture capital transactions:
Prev: 1/8/2016: Bottlenose venture capital transaction
Next: 1/11/2016: Grownetics venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs